^
    Back
    Association details:
    Biomarker:BCOR mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:azacitidine (DNMT inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    Cancers (Basel)
    Title:

    The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial

    Published date:
    05/18/2021
    Excerpt:
    ...newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group)…mutated BCOR (HR, 3.6, p = 0.0003) was associated with a shorter relapse-free survival (RFS).
    DOI:
    10.3390/cancers13102458
    Trial ID:
    FLUGAZA